KR940002114B1 - 티고제닌-셀로비오사이드의 제조방법 - Google Patents

티고제닌-셀로비오사이드의 제조방법 Download PDF

Info

Publication number
KR940002114B1
KR940002114B1 KR1019840004369A KR840004369A KR940002114B1 KR 940002114 B1 KR940002114 B1 KR 940002114B1 KR 1019840004369 A KR1019840004369 A KR 1019840004369A KR 840004369 A KR840004369 A KR 840004369A KR 940002114 B1 KR940002114 B1 KR 940002114B1
Authority
KR
South Korea
Prior art keywords
compound
formula
thigogenin
anomer
cellobiose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019840004369A
Other languages
English (en)
Korean (ko)
Other versions
KR850007432A (ko
Inventor
렌 맬리노 엠.
Original Assignee
메디칼 리서치 파운데이션 오브 오리건
원본미기재
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디칼 리서치 파운데이션 오브 오리건, 원본미기재 filed Critical 메디칼 리서치 파운데이션 오브 오리건
Publication of KR850007432A publication Critical patent/KR850007432A/ko
Application granted granted Critical
Publication of KR940002114B1 publication Critical patent/KR940002114B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0015—Details of inhalators; Constructional features thereof with inhalation check valves located upstream of the dispenser, i.e. not traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0016—Details of inhalators; Constructional features thereof with inhalation check valves located downstream of the dispenser, i.e. traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Cephalosporin Compounds (AREA)
KR1019840004369A 1984-04-20 1984-07-23 티고제닌-셀로비오사이드의 제조방법 Expired - Fee Related KR940002114B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US602,298 1984-04-20
US06/602,298 US4602005A (en) 1982-05-17 1984-04-20 Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis

Publications (2)

Publication Number Publication Date
KR850007432A KR850007432A (ko) 1985-12-04
KR940002114B1 true KR940002114B1 (ko) 1994-03-17

Family

ID=24410793

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840004369A Expired - Fee Related KR940002114B1 (ko) 1984-04-20 1984-07-23 티고제닌-셀로비오사이드의 제조방법

Country Status (16)

Country Link
US (1) US4602005A (cg-RX-API-DMAC7.html)
EP (1) EP0159431B1 (cg-RX-API-DMAC7.html)
JP (1) JPS60224697A (cg-RX-API-DMAC7.html)
KR (1) KR940002114B1 (cg-RX-API-DMAC7.html)
AT (1) ATE42959T1 (cg-RX-API-DMAC7.html)
AU (1) AU580005B2 (cg-RX-API-DMAC7.html)
CA (1) CA1246544A (cg-RX-API-DMAC7.html)
DE (1) DE3478114D1 (cg-RX-API-DMAC7.html)
DK (2) DK165839C (cg-RX-API-DMAC7.html)
ES (1) ES8601233A1 (cg-RX-API-DMAC7.html)
FI (2) FI82253C (cg-RX-API-DMAC7.html)
HU (1) HUT37802A (cg-RX-API-DMAC7.html)
IE (1) IE58015B1 (cg-RX-API-DMAC7.html)
NO (1) NO842990L (cg-RX-API-DMAC7.html)
NZ (1) NZ208961A (cg-RX-API-DMAC7.html)
ZA (1) ZA845690B (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4865850A (en) * 1986-09-08 1989-09-12 See/Shell Biotechnology, Inc. Dietary fat reduction
US5010185A (en) * 1989-06-13 1991-04-23 Pfizer Inc. Processes for tigogenin beta-cellobioside
US5091192A (en) * 1990-01-16 1992-02-25 Natur-All Systems, Inc. Bile salts permanently bound to insoluble cellulose as a dietary supplement
CA2079544A1 (en) * 1991-10-04 1993-04-05 Adam Weislaw Mazur Cholesterol lowering compounds
AU2753292A (en) * 1991-10-04 1993-05-03 Procter & Gamble Company, The Cholesterol lowering compounds and process for making them
WO1993011150A1 (en) * 1991-11-25 1993-06-10 Pfizer Inc. Method for making steroidal peracyl glycosides
US5294703A (en) * 1992-05-01 1994-03-15 Eastman Kodak Company Process for preparing α-D-cellobiose octaacetate
EP0647233A1 (en) * 1992-06-26 1995-04-12 Pfizer Inc. Steroidal beta-o-cellobioside heptaalkanoate process
US5629295A (en) * 1992-06-26 1997-05-13 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
CA2138042A1 (en) * 1992-06-26 1994-06-01 Frank R. Busch Process for steroidal peracyl glycosides
US5530107A (en) * 1992-10-15 1996-06-25 Pfizer Inc. Method for making steroidal peracyl glycosides
CA2161239A1 (en) * 1993-04-28 1994-11-10 Douglas J.M. Allen Spirostanyl glycosidal crystalline monohydrate
US5502038A (en) * 1993-06-21 1996-03-26 Medical Research Foundation Of Oregon Cholesterol sequestrant glycosides that inhibit intestinal cholesterol absorption
WO1995000158A1 (en) * 1993-06-25 1995-01-05 Bio-Sphere Technology Dietary supplement incorporating beta-sitosterol and pectin
ES2074006B1 (es) * 1993-07-05 1996-03-16 Pfizer Glicosidos esteroidales para tratar hipercolesterolemia.
US5698526A (en) * 1993-12-28 1997-12-16 Pfizer Inc. Steroidal glycosides
US5607841A (en) * 1994-06-20 1997-03-04 Lipinski; Boguslaw Preparation and proteolytic degradation of a macromolecular protein complex from fibrinogen
AU2453295A (en) * 1994-09-20 1996-04-19 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
WO1996038466A1 (en) * 1995-05-29 1996-12-05 Pfizer Inc. Steroidal glycosides
US5698527A (en) * 1995-08-08 1997-12-16 Merck & Co., Inc. Steroidal glycosides as antihyperlipidemic agents
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
PL195897B1 (pl) * 1998-03-26 2007-11-30 Phytopharm Plc Zastosowanie smilageniny
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US20020183305A1 (en) * 2001-01-26 2002-12-05 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
PL364178A1 (en) * 2001-01-26 2004-12-13 Schering Corporation Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
DK1355644T3 (da) * 2001-01-26 2006-10-23 Schering Corp Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
HU230253B1 (hu) * 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
IL156585A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
AU2002241956A1 (en) * 2001-01-26 2002-08-06 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
JP2004532868A (ja) * 2001-05-25 2004-10-28 シェーリング　コーポレイション アルツハイマー病の処置におけるアゼチジノン置換誘導体の使用
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
AU2002335770B2 (en) * 2001-09-21 2005-08-18 Merck Sharp & Dohme Corp. Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
JP2005504091A (ja) * 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
WO2004043457A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CA2517571C (en) * 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) * 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
EP1680189A2 (en) * 2003-11-05 2006-07-19 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
AU2003300732A1 (en) * 2003-12-31 2005-07-21 Council Of Scientific And Industrial Research Isolation of tigogenin pentaglycoside from chlorophytum nimonii
US7160866B2 (en) 2004-03-22 2007-01-09 Council Of Scientific And Industrial Research Isolation of tigogenin pentaglycoside from Chlorophytum nimonii

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2759171A1 (de) * 1977-12-31 1979-07-12 Roecar Holdings Nv Arzneimittel mit wirkung als prostaglandinsynthetaseninhibitor
DE2926463A1 (de) * 1978-07-05 1980-01-24 Roecar Holdings Nv Spiroketaline und ihre verwendung
US4260603A (en) * 1979-01-02 1981-04-07 Pegel Karl H Sterol glycoside with activity as prostaglandin synthetase inhibitor
US4242502A (en) * 1979-04-20 1980-12-30 United States Of America Enhancement of cholesterol combining properties of saponins
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis

Also Published As

Publication number Publication date
CA1246544A (en) 1988-12-13
DK14892A (da) 1992-02-06
ATE42959T1 (de) 1989-05-15
JPH0456840B2 (cg-RX-API-DMAC7.html) 1992-09-09
DK165839C (da) 1993-06-21
ES534553A0 (es) 1985-11-16
KR850007432A (ko) 1985-12-04
EP0159431B1 (en) 1989-05-10
FI900531A0 (fi) 1990-02-02
DK361084D0 (da) 1984-07-23
FI82253C (fi) 1991-02-11
FI82253B (fi) 1990-10-31
NZ208961A (en) 1988-01-08
EP0159431A2 (en) 1985-10-30
FI87792B (fi) 1992-11-13
AU580005B2 (en) 1988-12-22
DK165839B (da) 1993-01-25
HUT37802A (en) 1986-02-28
DK14892D0 (da) 1992-02-06
JPS60224697A (ja) 1985-11-09
ZA845690B (en) 1986-03-26
AU3097784A (en) 1985-10-24
NO842990L (no) 1985-10-21
ES8601233A1 (es) 1985-11-16
IE841904L (en) 1985-10-20
DK166213C (da) 1993-08-16
DE3478114D1 (en) 1989-06-15
US4602005A (en) 1986-07-22
EP0159431A3 (en) 1986-01-08
FI842935A0 (fi) 1984-07-23
DK166213B (da) 1993-03-22
FI87792C (fi) 1993-02-25
IE58015B1 (en) 1993-06-16
DK361084A (da) 1985-10-21
FI842935L (fi) 1985-10-21

Similar Documents

Publication Publication Date Title
KR940002114B1 (ko) 티고제닌-셀로비오사이드의 제조방법
US4113881A (en) Method of treating rheumatoid arthritis
RU2095366C1 (ru) Соединение, его фармацевтически приемлемая соль, фармацевтическая композиция
US3892852A (en) Pharmaceutical compositions containing cysteine derivatives
IL44670A (en) History of mycophenolic acid
WO1995010527A1 (en) 3,17-dihydroxy-3,7,16 and/or 17-methyl-androst-5-ene compounds, derivatives thereof, and their use
EP2527355B1 (en) Polymorphic and amorphous salt forms of squalamine dilactate
JPH05247078A (ja) 糖化合物、シアル酸含有糖鎖類生合成阻害剤、その製造方法、並びに新規な中間体
EP0348859A1 (en) 1,2-di-O-acyl glycero(DI)phosphate of L-carnitine and its derivatives, a process for their preparation and pharmaceutical formulations which contain them
US4582824A (en) Method for inhibiting activities of platelet activating factor
US3836656A (en) Substituted purines as hypolipidemics
US3453315A (en) 9-isopropylidenyl-9,10-dihydro-anthracene-10-carboxylic acid esters
GB2102812A (en) Therapeutically active compounds from species of rubia synthetic derivatives thereof, methods for the production thereof and pharmaceutical compositions comprising the same
KR20020050282A (ko) 베타-디-5-티옥실로스 유도체, 제조방법 및 약학적 용도
US4255573A (en) Imidazoindole derivatives and pharmaceutical compositions comprising imidazoindole derivatives
US4914234A (en) 10,10-Dihydro-10-((substituted-carbonyl)imino)-10-phenyl-10H-phenoxaphosphine, hydrochloride
US3767800A (en) Substituted ribofuranosides as hypolipidemics
US3655886A (en) Pharmacologically effective substance and process for preparing it
JP2527995B2 (ja) 生物学的活性を示す薬剤
US3873699A (en) Pharmacologically active substances isolated from {8 cadia ellisiana {b
US4866063A (en) Diol metabolites of 7-phenyl-1,2,4-triazolo[2,3-c]pyrimidines-5-amines
US4777290A (en) 10,10-dihydro-10-[(substituted-carbonyl)imino]-10-phenyl-10H-phenoxaphosphines
US4689324A (en) 10,10-dihydro-10-[(substituted-carbonyl)imino]-10-phenyl-10H-phenoxaphosphines compositions containing same and therapeutic methods of use
EP0340759A1 (en) Salts of O-mono (di)-acetyl-glycero-mono-(bis)-(di)-phosphates of L-acetyl-carnitine and of L-acetyl carnitine esters
US20030100515A1 (en) Benzophenone glycopyranosides, preparation and therapeutic use

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 19980317

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 19990318

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 19990318